Purchase this article with an account.
Grace Shih, Jesse berry, Stavros Moysidis, A. Linn Murphree, Rima Jubran, Jonathan W Kim; Persistence of Subretinal Fluid and the Risk of Enucleation in Group D Retinoblastoma Eyes. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):6057. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the association of persistent subretinal fluid (SRF) and the need for enucleation in Group D eyes of bilateral retinoblastoma treated with chemoreduction.
53 Group D eyes were evaluated for the presence of SRF at diagnosis. They were subsequently treated with primary chemoreduction, using a 3 drug chemotherapy regimen. Globe survival analysis was used to evaluate whether persistence of subretinal fluid was associated with persistent tumor activity after chemoreduction and a worse overall outcome (i.e. enucleation). Logistic regression analysis was used to assess the association between duration of SRF and risk for enucleation.
79.25% (n=42) of Group D eyes exhibited SRF at diagnosis. Of these 42 eyes, 25 eyes showed subretinal fluid that persisted after the first round of chemotherapy. 9 eyes demonstrated continued SRF after 3 cycles of chemotherapy and 2 eyes continued with fluid at 6 months. Ten eyes ultimately required enucleation (10/53 or 18.9%). Only one of the 10 enucleated eyes demonstrated persistent SRF at the time of enucleation. 8 of 10 eyes contained histologic evidence of viable tumor cells. There was no statistically significant association between the persistence of SRF and risk for enucleation.
We hypothesized that the persistence of subretinal fluid during chemotherapy was a risk factor for enucleation. However, the duration of SRF was not found to be an independent predictor of whether Group D eyes will ultimately require enucleation following chemoreduction.
This PDF is available to Subscribers Only